KLISBio develops a silk fibroin-based tissue engineering platform for regenerative medicine, focusing on applications in orthopedic and vascular repair. This technology provides a biocompatible scaffold that enhances cell proliferation and tissue regeneration, addressing the need for effective solutions in soft tissue repair.
Funding
Funding not disclosed
Founders
Product
Problem
Current regenerative medicine approaches for soft tissue repair often lack biocompatible scaffolds that effectively promote cell proliferation and tissue regeneration. This limitation hinders the body's natural healing processes, leading to suboptimal outcomes in orthopedic and vascular applications.
Solution
KLISBio has developed a silk fibroin-based tissue engineering platform designed to enhance regenerative outcomes in orthopedic and vascular repair. Their technology utilizes silk fibroin, a biocompatible material known for its ability to promote cell proliferation and stimulate in-vivo tissue regeneration. The silk fibroin scaffolds provide a favorable environment for cells to grow, offering a unique combination of biological and mechanical properties. KLISBio's platform targets various clinical indications within the orthopedic and vascular markets, offering versatile processing options and programmed degradation profiles.
Target Audience
The primary audience includes orthopedic surgeons, vascular surgeons, and other healthcare professionals involved in regenerative medicine and soft tissue repair.
Features
- Silk fibroin-based scaffolds for enhanced biocompatibility and cell proliferation.
- Versatile processing options for tailoring scaffolds to specific applications.
- Programmed degradation profiles to match tissue regeneration rates.
- Scaffolds are free from cells, nuclear remnants, and genetic material.
- Favorable morphological, chemical, and mechanical cues for cell growth.
- Promotes angiogenesis to support tissue regeneration.